Market Overview:
The global infectious diseases market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases, growing demand for novel antibiotics and antivirals, and rising funding for R&D in the field of infectious diseases. The antibacterial drugs segment is expected to account for the largest share of the global infectious diseases market in 2018. This segment is projected to grow at a CAGR of 6.8% from 2018 to 2030 due to the increasing incidence of bacterial infections across the globe. The antiviral drugs segment is projected to grow at a CAGR of 7% from 2018to 2030 due its growing use in treatment regimens for various viral infections such as HIV/AIDS, hepatitis B &C, and herpes simplex virus (HSV).
Product Definition:
Infectious diseases are illnesses caused by viruses, bacteria, or other organisms. Infectious diseases can be spread through the air, water, food, or contact with infected people or animals. Some infectious diseases are easily treated with antibiotics while others can be deadly. Infectious diseases are a major cause of death and illness around the world.
Antibacterial Drugs:
Antibacterial drugs are the medicines used to treat bacterial infections. The growing prevalence of infectious diseases and increasing demand for antibacterial drugs is expected to drive the global market during the forecast period. According to CDC, every year around 2 million people in U.S get infected with HIV, out of which 1 million patients die because they cannot afford antiretroviral therapy or treatment.
Antiviral Drugs:
Antiviral drugs are used to treat or reduce the duration and severity of an infection. The most common infectious diseases that require antiviral drugs include HIV, malaria, tuberculosis, chickenpox, influenza (flu), hepatitis A & B and Human Papillomavirus (HPV). According to the Centers for Disease Control and Prevention (CDC), around 36 million people in U.S.
Application Insights:
Based on application, the global infectious diseases market is segmented into hospitals/clinical laboratories, reference laboratories, academic/research institutes and others. Hospitals/clinical laboratories held the largest share in 2017 owing to increasing prevalence of infectious diseases and a rising number of hospital-based diagnostic centers. This trend is expected to continue over the forecast period as these institutions focus on providing rapid diagnosis for patients in order to minimize treatment time and costs.
Increasing travel activities across various regions coupled with exposure to new pathogens has resulted in an increased incidence rate of novel viruses such as COVID-19 that cause severe disease outbreaks.
Regional Analysis:
The Asia Pacific dominated the global market in 2017. This can be attributed to increasing awareness about infectious diseases, rising healthcare expenditure, and a large number of patients in this region. The high prevalence of COVID-19 cases in countries such as India and China is expected to drive the demand for various drugs used for treating these infections over the forecast period.
North America accounted for a significant share owing to factors such as favorable reimbursement policies and increasing government initiatives pertaining to disease control & prevention.
Growth Factors:
- Increasing incidence of infectious diseases: The incidence of infectious diseases is increasing at a rapid pace across the globe. This is primarily attributed to the changing lifestyle and environmental conditions. This, in turn, is propelling the growth of the infectious diseases market.
- Growing demand for vaccines and therapeutics: The demand for vaccines and therapeutics for treating various types of infections is growing rapidly due to the increasing prevalence of these diseases. This is fueling the growth of the global infectious diseases market.
- Rising awareness about preventive measures: There has been a significant rise in awareness among people about preventive measures against various types of infections in recent years. This is aiding in propellingthe growthof Infectious Diseases market globally .
Scope Of The Report
Report Attributes
Report Details
Report Title
Infectious Diseases Market Research Report
By Type
Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Antiparasitic Drugs
By Application
Hospitals/Clinical Laboratories, Reference Laboratories, Academic/Research Institutes, Other
By Companies
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Vertex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Infectious Diseases Market Report Segments:
The global Infectious Diseases market is segmented on the basis of:
Types
Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Antiparasitic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals/Clinical Laboratories, Reference Laboratories, Academic/Research Institutes, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Pfizer
- AbbVie
- Astellas Pharma
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Chimerix Pharmaceuticals
- Cubist
- Eli Lilly
- Isis Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis
- Sanofi
- Vertex
Highlights of The Infectious Diseases Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
- Antiparasitic Drugs
- By Application:
- Hospitals/Clinical Laboratories
- Reference Laboratories
- Academic/Research Institutes
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Infectious Diseases Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Infectious diseases are illnesses caused by viruses, bacteria, or other microorganisms. They can be serious and even life-threatening. Infectious diseases can be spread through contact with saliva, blood, mucus, or other body fluids that contain the virus or bacteria. Some infectious diseases are also spread through contact with objects and surfaces that have been contaminated with the virus or bacteria.
Some of the major players in the infectious diseases market are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Vertex.
The infectious diseases market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Infectious Diseases Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Infectious Diseases Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Infectious Diseases Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Infectious Diseases Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Infectious Diseases Market Size & Forecast, 2018-2028
4.5.1 Infectious Diseases Market Size and Y-o-Y Growth
4.5.2 Infectious Diseases Market Absolute $ Opportunity
Chapter 5 Global Infectious Diseases Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Infectious Diseases Market Size Forecast by Type
5.2.1 Antibacterial Drugs
5.2.2 Antiviral Drugs
5.2.3 Antifungal Drugs
5.2.4 Antiparasitic Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Infectious Diseases Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Infectious Diseases Market Size Forecast by Applications
6.2.1 Hospitals/Clinical Laboratories
6.2.2 Reference Laboratories
6.2.3 Academic/Research Institutes
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Infectious Diseases Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Infectious Diseases Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Infectious Diseases Analysis and Forecast
9.1 Introduction
9.2 North America Infectious Diseases Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Infectious Diseases Market Size Forecast by Type
9.6.1 Antibacterial Drugs
9.6.2 Antiviral Drugs
9.6.3 Antifungal Drugs
9.6.4 Antiparasitic Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Infectious Diseases Market Size Forecast by Applications
9.10.1 Hospitals/Clinical Laboratories
9.10.2 Reference Laboratories
9.10.3 Academic/Research Institutes
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Infectious Diseases Analysis and Forecast
10.1 Introduction
10.2 Europe Infectious Diseases Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Infectious Diseases Market Size Forecast by Type
10.6.1 Antibacterial Drugs
10.6.2 Antiviral Drugs
10.6.3 Antifungal Drugs
10.6.4 Antiparasitic Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Infectious Diseases Market Size Forecast by Applications
10.10.1 Hospitals/Clinical Laboratories
10.10.2 Reference Laboratories
10.10.3 Academic/Research Institutes
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Infectious Diseases Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Infectious Diseases Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Infectious Diseases Market Size Forecast by Type
11.6.1 Antibacterial Drugs
11.6.2 Antiviral Drugs
11.6.3 Antifungal Drugs
11.6.4 Antiparasitic Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Infectious Diseases Market Size Forecast by Applications
11.10.1 Hospitals/Clinical Laboratories
11.10.2 Reference Laboratories
11.10.3 Academic/Research Institutes
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Infectious Diseases Analysis and Forecast
12.1 Introduction
12.2 Latin America Infectious Diseases Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Infectious Diseases Market Size Forecast by Type
12.6.1 Antibacterial Drugs
12.6.2 Antiviral Drugs
12.6.3 Antifungal Drugs
12.6.4 Antiparasitic Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Infectious Diseases Market Size Forecast by Applications
12.10.1 Hospitals/Clinical Laboratories
12.10.2 Reference Laboratories
12.10.3 Academic/Research Institutes
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Infectious Diseases Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Infectious Diseases Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Infectious Diseases Market Size Forecast by Type
13.6.1 Antibacterial Drugs
13.6.2 Antiviral Drugs
13.6.3 Antifungal Drugs
13.6.4 Antiparasitic Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Infectious Diseases Market Size Forecast by Applications
13.10.1 Hospitals/Clinical Laboratories
13.10.2 Reference Laboratories
13.10.3 Academic/Research Institutes
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Infectious Diseases Market: Competitive Dashboard
14.2 Global Infectious Diseases Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche
14.3.2 Gilead Sciences
14.3.3 GlaxoSmithKline
14.3.4 Johnson & Johnson
14.3.5 Merck
14.3.6 Pfizer
14.3.7 AbbVie
14.3.8 Astellas Pharma
14.3.9 AstraZeneca
14.3.10 Bayer
14.3.11 Bristol-Myers Squibb
14.3.12 Chimerix Pharmaceuticals
14.3.13 Cubist
14.3.14 Eli Lilly
14.3.15 Isis Pharmaceuticals
14.3.16 Mitsubishi Tanabe Pharma
14.3.17 Novartis
14.3.18 Sanofi
14.3.19 Vertex
